CovidVax show full list
COVID-19 VACCINE:

Adjuvanted recombinant protein

researcher:
Anhui Zhifei Longcom Biopharma + Institute of Microbiology Chinese Academy of Sciences
http://en.zhifeishengwu.com/about/zfgk/
http://english.im.cas.cn/
(China)
vaccine type: Protein subunit
Distribution updates
currently no distribution info
Human Testing updates (clinical trials)

PHASE 1

 

started June 22 2020

with 50 healthy volunteers aged 18-59

trial location: China

» clinical trial details

PHASE 1

 

started October 30 2020

with 216 healthy volunteers aged 18+

trial location: China

» clinical trial details

PHASE 1-2

 

started August 19 2020

with 50 healthy volunteers aged 60+

trial location: China

» clinical trial details

PHASE 2

 

started July 12 2020

with 900 healthy volunteers aged 18-59

trial location: China

» clinical trial details

PHASE 3

 

started November 6 2020

with 29000 healthy volunteers aged 18+

trial location: China

» clinical trial details

Dec 23AnhuiZhifei's vaccine was found to be safe and triggered immune responses in early and mid-stage trials (by reuters.com)
Dec 11Some 5000 volunteers in Uzbekistan will take part in AnhuiZhifei's Phase 3 human trials which officially kicked off yesterday (by yicaiglobal.com)
Jul 15Second Phase of AnhuiZhifei's vaccine has started to evaluate the safety and immunogenicity (by ichongqing.info)
Jul 09AnhuiZhifei's vaccine moved into Phase 2 human trials just 3 weeks after starting clinical studies (by reuters.com)
Jun 29AnhuiZhifei was the second recombinant subunit vaccine to enter clinical trials in the world (by ichongqing.info)
Jun 23China has approved AnhuiZhifei's vaccine to begin human testing (by reuters.com)
Animal Testing updates (pre-clinical trials)
start date: February 2020
Mar 01AnhuiZhifei's vaccine reportedly entered the stage of animal experimentation in February 2020 (by asiabiotech.com)
early development updates
currently no early development info






contact | about | ©2020 CovidVax.org project